SCHEMBL2946790

SCHEMBL2946790

O=C(Nc1ccc(Cl)cn1)c1oc2cccnc2c1NC(=O)C1CCC(N2CCNCC2=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 7/20 0.41
▸ F10 P00742 4/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ RAB9A P51151 3/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ TP53 P04637 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ TSHR P16473 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ DEGS1 O15121 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ PTBP1 P26599 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946780 1.00 NPY5R (0.41) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2948874 0.89 NPY5R (0.50) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2948876 0.89 NPY5R (0.50) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2947431 0.87 F10 (0.41) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2947435 0.87 F10 (0.41) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2952053 0.87 F10 (0.42) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2952052 0.87 F10 (0.42) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL13290409 0.85 NPY5R (0.51) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL13290416 0.85 SMN1; SMN2 (0.42) NPY5RF10SMN1; SMN2RAB9AMAPK1
SCHEMBL2950495 0.85 F10 (0.42) NPY5RF10SMN1; SMN2RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 NPY5R 805/4885F10 4/4885SMN1; SMN2 4447/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 NPY5R 589/4885F10 4/4885SMN1; SMN2 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback